Blog Post Image: Research Resilience: Disappointing Alzheimer’s trial yields new ideas

Bapineuzumab and placebo. DAD (Disability Assessment for Dementia) scores worsened on average during the 78-week trial, with “bapi” (dotted blue line) showing no improvement over placebo. Image credit: Brown University